Please login to the form below

Not currently logged in
Email:
Password:

LMTX

This page shows the latest LMTX news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with AC Immune on tau drug for Alzheimer’s

Lilly partners with AC Immune on tau drug for Alzheimer’s

The company credited with pioneering the tau hypothesis in AD is TauRx, although its aggregation inhibitor LMTX disappointed in an 891-paient phase 3 trial reported in 2016.

Latest news

  • AbbVie takes anti-tau drug into phase II for Alzheimer's AbbVie takes anti-tau drug into phase II for Alzheimer's

    Whether tau-targeting drugs can do better remains to be seen. Last year, TauRx's tau aggregation inhibitor LMTX failed to slow cognitive decline in three phase III trials - two in

  • Tau protein drug fails late-stage trial Tau protein drug fails late-stage trial

    LMTX is thought to reduce the accumulation of the tau protein, which normally stabilizes neurons, into potentially toxic tangles. ... The LMTX data were presented at the Alzheimer's Association International Conference in Toronto.

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...